Business

Wuhan General Group Financials Update

Wuhan General Group Financials Update.

articleWuhan General Group (china), Inc.December 4, 20204/news/wuhan-general-group-financials-update
Wuhan General Group Financials Update

About this update from Wuhan General Group (china), Inc.

CAPE TOWN, SA / ACCESSWIRE / December 4, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update to its shareholders:The Company is pleased to inform its shareholders that with OTCIQ having just granted access to the platform, it has started the process of updating its profile on OTCMarket. In addition, the Company is planning to post financials and information disclosure in the coming weeks. Our filings are currently being prepared and we anticipate all filings to be uploaded by December 8th. Once OTCMarket has reviewed our filings and approved them by moving us to Limited Information, we will proceed to file and upload the required opinion letter and have Current Information status tier by mid-December."This is a big first step in a series of very important milestones for Wuhan. Having a Current Status allows for much greater flexibility enabling us to execute some rather nifty deliverables." said Jeff Robinson, CEO of Wuhan General Group.Our filings can be viewed on OTC Market' s website at the following link: https://www.otcmarkets.com/stock/WUHN/disclosure.About Wuhan General Group, Inc./ M2Bio Sciences, Inc.Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".For further information:Publicly traded company (OTC PINK:WUHN)Website: www.m2bio.coE-mail:[email protected] us on Twitter: https://twitter.com/m2bioFollow us on Facebook: http://www.facebook.com/m2bioForward-Looking Statements:Safe Harbour Statement - In addition to historical information...

View stock analysis, news, and events for Wuhan General Group (china), Inc.